Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components
NCT ID: NCT04895059
Last Updated: 2021-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2017-04-30
2018-01-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
NCT04862962
Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe
NCT02127320
to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers
NCT02289430
Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients
NCT01164397
Drug Interaction Statin
NCT02089061
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: Rosuvastatin / Ezetimibe fixed dose
In fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg / 10 mg Administration way: oral
Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose
Form: Tablets Dosage: 20 mg Adminstration way: Oral
Group B: Rosuvastatin (Crestor®)
Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral
Rosuvastatin 20mg
Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
Group C: Ezetimibe (Ezetrol®)
Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration wat: Oral
Ezetimibe 10mg
Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose
Form: Tablets Dosage: 20 mg Adminstration way: Oral
Rosuvastatin 20mg
Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
Ezetimibe 10mg
Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women of childbearing age should have a family planning method (including barrier methods, non-hormonal intrauterine devices or bilateral tubal obstruction) or practice abstinence as a lifestyle during the development of the clinical study.
* Volunteers must be healthy, a criterion determined by the results of a complete medical history carried out by the doctors of the Clinical Research site and the laboratory and cabinet studies carried out in certified Clinical Laboratories.
* The limits of variation allowed within normality in the selection visit will be: blood pressure (sitting) from 90 to 130 mmHg systolic and 60 to 90 mmHg diastolic, heart rate between 50 and 100 beats per minute and respiratory rate between 14 and 20 breaths per minute according to current SOP with code CLI-DES-008 " Measure vital sign".
* The vital signs will be taken after 5 minutes of rest in the sedent position.
* The laboratory and office tests that were carried out for the inclusion of the subjects to the study will be: 1. Complete hematic biometry with differential count: Leukocytes, erythrocytes, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean concentration of corpuscular hemoglobin, distribution width of erythrocytes, platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils. 2.27-element blood chemistry: glucose, urea, BUN, creatinine, BUN / creatinine ratio, uric acid, cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, non-HDL cholesterol, atherogenic index, total proteins, albumin, globulins, A / ratio G, total bilirubin, direct bilirubin, indirect bilirubin, TGO, TGP, total alkaline phostatase, gamma-glutamyltranspeptidase, DHL, iron, calcium sodium, potassium and chlorine. 3.General urine test. Physical examination (color, appearance, density); chemical test (pH, leukocytes, nitrites, proteins, glucose, ketones, bilirubin, urobilinogen, hemoglobin); microscopic examination (leukocytes, erythrocytes, dysformic erythrocytes, casts, crystals, pavement cells, renal tubular cells, mucoid networks, bacteria and yeasts. 4. Hepatitis B and C test: HBV surface antigen and anti-HCV antibody. 5. HIV test: Anti-HIV 1 and 2 antibodies. 6. VDRL test. 7. Urine drug abuse test at screening visit and approximately 12 hours prior to drug administration. 8. Online alcohol detection test approximately 12 hours prior to drug admission. 9. Serum pregnancy test at screening visit and urine pregnancy test (qualitative) approximately 12 hours before drug administration. 10. 12-lead electrocardiogram (valid for no more than 3 months).
Exclusion Criteria
* Volunteers who require any medication during the course of the study other than the medication being studied.
* Volunteers with a history of dyspepsia, gastritis, esophagitis, duodenal or gastric ulcer.
* History of hereditary galactose intolerance, Lapp lactase deficiency, or glucose or galactose malabsorption.
* Volunteers who have been exposed to medications known as liver enzyme inducers or inhibitors or who have taken potentially toxic medications within 30 days prior to the start of the study.
* Volunteers who have received any medications, including vitamins (with or without a prescription) or herbal remedies 30 days (or 7 half-lives) prior to the start of the study.
* Current or recent use of fibrates, niacin, cyclosporine, and protease inhibitors.
* History of muscle toxicity with another HMG-CoA inhibitor or fibrates.
* Volunteers who have been hospitalized for any problem during the six months prior to the start of the study.
* Subjects allergic to any medicine, food or substance. Subjects who have ingested alcohol and / or carbonated and / or xanthine-containing beverages (coffee, tea, cocoa, chocolate, mate, cola soft drinks) or who have ingested charcoal-grilled food or grapefruit juice within 10 hours prior to the start of the hospitalization period, or subjects who smoked tobacco within 10 hours prior to the start of the study.
* Subjects who have donated or lost 450 ml or more of blood within the 60 days prior to the start of the study.
* Subjects with a history of abuse and dependence on alcohol or psychoactive substances.
* Volunteers requiring a special diet for any reason, for example vegetarian.
* Incapacity of any kind that makes it impossible for the volunteer to understand the nature, objective and possible consequences of the study.
* Evidence of uncooperative attitude during the study.
* Volunteers with positive drug abuse, pregnancy and / or alcohol testing.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratorios Silanes S.A. de C.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Araceli G Medina Nolasco, M.D
Role: PRINCIPAL_INVESTIGATOR
Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratorio Silanes, S.A. de C.V.
Mexico City, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chu NN, Chen WL, Xu HR, Li XN. Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. Clin Drug Investig. 2012 Dec;32(12):791-8. doi: 10.1007/s40261-012-0013-5.
Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30.
Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009 Apr 30;360(18):1851-61. doi: 10.1056/NEJMoa0900241. Epub 2009 Mar 29.
Kanazawa I, Yamaguchi T, Yamauchi M, Sugimoto T. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia. Intern Med. 2009;48(21):1869-73. doi: 10.2169/internalmedicine.48.2645. Epub 2009 Nov 2.
Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, Kim W, Nam CW, Rhee MY, Park TH, Hong TJ, Park S, Ahn Y, Lee N, Jeon HK, Jeon DW, Han KR, Moon KW, Chae IH, Kim HS. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016 Oct;34(5):371-82. doi: 10.1111/1755-5922.12213.
Lorgelly PK, Briggs AH, Wedel H, Dunselman P, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J, Janosi A, van Veldhuisen DJ, Barrios V, Fonseca C, McMurray JJ; CORONA Study Group. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. Eur J Heart Fail. 2010 Jan;12(1):66-74. doi: 10.1093/eurjhf/hfp172.
McKenney JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm. 2005 May 15;62(10):1033-47. doi: 10.1093/ajhp/62.10.1033.
Nakano T, Inoue I, Takenaka Y, Ono H, Katayama S, Awata T, Murakoshi T. Ezetimibe Promotes Brush Border Membrane-to-Lumen Cholesterol Efflux in the Small Intestine. PLoS One. 2016 Mar 29;11(3):e0152207. doi: 10.1371/journal.pone.0152207. eCollection 2016.
Leiter LA, Betteridge DJ, Farnier M, Guyton JR, Lin J, Shah A, Johnson-Levonas AO, Brudi P. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab. 2011 Jul;13(7):615-28. doi: 10.1111/j.1463-1326.2011.01383.x.
Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M; COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009 Nov;73(11):2110-7. doi: 10.1253/circj.cj-09-0358. Epub 2009 Oct 5.
Yu CC, Lai WT, Shih KC, Lin TH, Lu CH, Lai HJ, Hanson ME, Hwang JJ. Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. BMC Res Notes. 2012 May 23;5:251. doi: 10.1186/1756-0500-5-251.
Related Links
Access external resources that provide additional context or updates about the study.
NORMA oficial Mexicana NOM-177-SSA1-2013, Que establece las pruebas y procedimientos para para demostrar que un medicamento es intercambiable. Requisitos a que deben sujetarse los Terceros Autorizados que realicen las pruebas de intercambiabilidad
NORMA Oficial Mexicana NOM-220-SSA1-2016, Instalación y operación de la farmacovigilancia.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RSEZ-25-SIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.